Columbia Laboratories, Inc. engages in the research, development, manufacture, and commercialization of women's healthcare and endocrinology products. It offers its products through the utilization of its bioadhesive delivery system technology. The company markets vaginal progesterone gel products to assist women who are infertile become pregnant in the United States, which include CRINONE 8% for technical procedures to reproductive endocrinologists; PROCHIEVE 8% to obstetricians and gynecologists; and PROCHIEVE 4% for treatment of secondary amenorrhea. It also provides vaginal gel women's products, such as Replens, a vaginal moisturizer for replenishment of vaginal moisture; RepHresh vaginal gel that eliminates vaginal odor; and Advantage-S, a female contraceptive gel. In addition, the company offers STRIANT, a testosterone buccal system for the treatment of hypogonadism in men; and Advance Formula Legatrin PM for the relief of occasional pain and sleeplessness associated with minor muscle aches. Further, it engages in clinical development activities of vaginally-administered lidocaine to prevent and treat dysmenorrheal, as well as vaginally-administered carbamide peroxide for treating vaginal infections; and testosterone progressive hydration vaginal tablet for women, which completed phase I trial. Columbia Laboratories has a development and license agreement with Ardana Biosciences, Ltd. to develop terbutaline vaginal gel product candidate for the treatment of infertility, dysmenorrheal, and endometriosis.